{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:41:27Z","timestamp":1770489687061,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori)<\/jats:italic> prevalence is lower in patients with inflammatory bowel disease (IBD) than in those without IBD, suggesting that <jats:italic>H. pylori<\/jats:italic> plays a protective role in IBD. It has been reported that IBD may occur due to <jats:italic>H. pylori<\/jats:italic> eradication; however, it is unclear whether <jats:italic>H. pylori<\/jats:italic> eradication increases the incidence of IBD. Moreover, the effect of <jats:italic>H. pylori<\/jats:italic> eradication on IBD activity is unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 11-year-old boy diagnosed with ulcerative colitis (UC) was in clinical remission, with treatment involving 5-aminosalicylic acid. Fecal calprotectin (FC) level had decreased to 33.2\u00a0mg\/kg, indicating mucosal healing. At age 12, he experienced epigastric pain on an empty stomach, which was relieved with dietary intake. His FC level was elevated without UC symptoms, such as diarrhea and bloody stools. He was diagnosed with <jats:italic>H. pylori<\/jats:italic> duodenal ulcer. <jats:italic>H. pylori<\/jats:italic> eradication (clarithromycin and amoxicillin for 7\u00a0days and a proton-pump inhibitor) led to symptom improvement the day after treatment initiation. However, he developed diarrhea and his FC level remained high despite improvement in duodenal ulcer symptoms and endoscopic findings of <jats:italic>H. pylori<\/jats:italic> eradication. Colonoscopy results indicated UC relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:italic>H. pylori<\/jats:italic> eradication may worsen UC activity. However, further studies are required as this case report involved only one pediatric patient with increased UC activity after <jats:italic>H. pylori<\/jats:italic> eradication<jats:italic>.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-02010-1","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:12:12Z","timestamp":1636546332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-9110","authenticated-orcid":false,"given":"Yuji","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigemi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"2010_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"2010_CR2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","volume":"146","author":"AD Kostic","year":"2014","unstructured":"Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489\u201399.","journal-title":"Gastroenterology"},{"key":"2010_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2036.2011.04969.x","volume":"35","author":"A Sonnenberg","year":"2012","unstructured":"Sonnenberg A, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:469\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"2010_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/gutjnl-2015-310545","volume":"66","author":"N Gastano-Rodrigeuez","year":"2017","unstructured":"Gastano-Rodrigeuez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut. 2017;66:235\u201349.","journal-title":"Gut"},{"key":"2010_CR5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/01.mib.0000235100.09231.d7","volume":"12","author":"A Tursi","year":"2006","unstructured":"Tursi A. Onset of Crohn\u2019s disease after Helicobacter pylori eradication. Inflamm Bowel Dis. 2006;12:1008\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"2010_CR6","unstructured":"Jovanovic IR, Milosavjevic TN, Jankovic GP, Micev MM, Dugalic PD, Saranovic D, et al. Clinical onset of the Crohn\u2019s disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases? Med Sci Monit. 2001;7:137\u201341."},{"key":"2010_CR7","first-page":"e115","volume":"20","author":"M Chiba","year":"2016","unstructured":"Chiba M, Tsuji T, Takahashi K, Komatsu M, Sugawara T, Ono I. Onset of ulcerative colitis after Helicobacter pylori eradication therapy: A case report. Perm J. 2016;20:e115\u20138.","journal-title":"Perm J"},{"key":"2010_CR8","doi-asserted-by":"crossref","unstructured":"Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ. 2014;348:g3174.","DOI":"10.1136\/bmj.g3174"},{"key":"2010_CR9","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1111\/j.1572-0241.2008.02158.x","volume":"103","author":"KT Thia","year":"2008","unstructured":"Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167\u201382.","journal-title":"Am J Gastroenterol"},{"key":"2010_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.7150\/ijms.6934","volume":"10","author":"X Jin","year":"2013","unstructured":"Jin X, Chen YP, Chen SH, Xiang Z. Association between Helicobacter Pylori infection and ulcerative colitis - - a case control study from China. Int J Med Sci. 2013;10:1479\u201384.","journal-title":"Int J Med Sci"},{"key":"2010_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.5217\/ir.2018.00044","volume":"16","author":"S Shinzaki","year":"2018","unstructured":"Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, et al. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res. 2018;16:609\u201318.","journal-title":"Intest Res"},{"key":"2010_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/ibd\/izy107","volume":"24","author":"H Zhang","year":"2018","unstructured":"Zhang H, Dai Y, Liu Y, Wu T, Li J, Wang X, et al. Helicobacter pylori colonization protects against chronic experimental colitis by regulating Th17\/Treg balance. Inflamm Bowel Dis. 2018;24:1481\u201392.","journal-title":"Inflamm Bowel Dis"},{"key":"2010_CR13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1177\/2050640618793564","volume":"6","author":"AG Gravina","year":"2018","unstructured":"Gravina AG, Prevete N, Tuccillo C, Musis CD, Romano L, Federico A, et al. Peptide Hp(2\u201320) accelerates healing of TNBS-induced colitis in the rat. United European Gastroenterol J. 2018;6:1428\u201336.","journal-title":"United European Gastroenterol J"},{"key":"2010_CR14","doi-asserted-by":"crossref","unstructured":"Chen Y, Huang J, Li H, Li P, Xu C. Serum exomes derived from Hp-positive gastritis patients inhibit MCP-1 and MIP-1\u03b1 expression via NLRP12-Notch signaling pathway in intestinal epithelial cells and improve DSS-induced colitis in mice. Int Immunopharmacol. 2020;88:107012.","DOI":"10.1016\/j.intimp.2020.107012"},{"key":"2010_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","volume":"22","author":"E Zittan","year":"2016","unstructured":"Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22:623\u201330.","journal-title":"Inflamm Bowel Dis"},{"key":"2010_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","volume":"19","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamma Bowel Dis. 2013;19:332\u201341.","journal-title":"Inflamma Bowel Dis"},{"key":"2010_CR17","doi-asserted-by":"crossref","unstructured":"Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, et al. Evaluation of serum leucine-rich alpha-2 glycoprotein as a new inflammatory biomarker of inflammatory bowel disease. Mediators Inflamm. 2021;8825374.","DOI":"10.1155\/2021\/8825374"},{"key":"2010_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","volume":"114","author":"R Ungaro","year":"2019","unstructured":"Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A treat-to-target update in ulcerative colitis: A systematic review. Am J Gastroenterol. 2019;114:874\u201383.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:14:16Z","timestamp":1636546456000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2010"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02010-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to participate is not applicable to this article as it is a case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"424"}}